Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances.
Negredo E, Higueras C, Adell X, Martinez JC, Martinez E, Puig J, Fumaz CR, Muñoz-Moreno JA, Perez-Alvarez N, Videla S, Estany C, Cinquegrana D, Gonzalez-Mestre V, Clotet B. Negredo E, et al. Among authors: videla s. AIDS Patient Care STDS. 2006 Dec;20(12):829-37. doi: 10.1089/apc.2006.20.829. AIDS Patient Care STDS. 2006. PMID: 17192148
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Ballesteros AL, Miró O, López S, Fuster D, Videla S, Martínez E, Garrabou G, Salas A, Côté H, Tor J, Rey-Joly C, Planas R, Clotet B, Tural C. Ballesteros AL, et al. Among authors: videla s. Antivir Ther. 2004 Dec;9(6):969-77. Antivir Ther. 2004. PMID: 15651755 Clinical Trial.
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
Bonjoch A, Paredes R, Galvez J, Miralles C, Videla S, Martínez E, Miranda J, Muñoz-Moreno JA, De la Torre J, Prieto A, Vilades C, Clotet B; SimplifiHAART Study Group. Bonjoch A, et al. Among authors: videla s. J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):313-6. doi: 10.1097/01.qai.0000164249.33851.3a. J Acquir Immune Defic Syndr. 2005. PMID: 15980691 Clinical Trial.
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.
Fuster D, Huertas JA, Gómez G, Solà R, González García J, Vilaró J, Pedrol E, Force L, Tor J, Sirera G, Videla S, Planas R, Clotet B, Tural C; PEG-TOX Research Group. Fuster D, et al. Among authors: videla s. Antivir Ther. 2005;10(7):841-7. Antivir Ther. 2005. PMID: 16312180 Clinical Trial.
Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3.
Sirera G, Videla S, López-Blázquez R, Llatjos M, Tarrats A, Castellà E, Grane N, Tural C, Rey-Joly C, Clotet B. Sirera G, et al. Among authors: videla s. J Antimicrob Chemother. 2008 Jan;61(1):191-4. doi: 10.1093/jac/dkm412. Epub 2007 Oct 31. J Antimicrob Chemother. 2008. PMID: 17977910
216 results